The DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index; 9 of the 11 sources its claims cite were checked for support.
Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X
Open accessAbstract
CAH-X is a hypermobility-type Ehlers–Danlos syndrome connective tissue dysplasia affecting approximately 15% of patients with 21-hydroxylase deficiency (21-OHD) congenital adrenal hyperplasia (CAH) due to contiguous deletion of CYP21A2 and TNXB genes. The two most common genetic causes of CAH-X are CYP21A1P-TNXA/TNXB chimeras with pseudogene TNXA substitution for TNXB exons 35–44 (CAH-X CH-1) and TNXB exons 40–44 (CAH-X CH-2). A total of 45 subjects (40 families) from a cohort of 278 subjects (135 families of 21-OHD and 11 families of other conditions) were found to have excessive TNXB exon 40 copy number as measured by digital PCR. Here, we report that 42 subjects (37 families) had at least one copy of a TNXA variant allele carrying a TNXB exon 40 sequence, whose overall allele frequency was 10.3% (48/467). Most of the TNXA variant alleles were in cis with either a normal (22/48) or an In2G (12/48) CYP21A2 allele. There is potential interference with CAH-X molecular genetic testing based on copy number assessment, such as with digital PCR and multiplex ligation-dependent probe amplification, since this TNXA variant allele might mask a real copy number loss in TNXB exon 40. This interference most likely happens amongst genotypes of CAH-X CH-2 with an in trans normal or In2G CYP21A2 allele.
Overview
CoChat Summary
## TL;DR
This study shows that a common TNXA pseudogene variant carrying TNXB exon 40-like sequence can inflate TNXB exon 40 copy-number signals and potentially mask true CAH-X CH-2 deletions in molecular testing. In a cohort of 278 subjects, the variant was found in 42 subjects from 37 families, with an overall allele frequency of 10.3% (48/467).
## Key findings
- Among 278 screened subjects, 45 from 37 unrelated families had excessive TNXB exon 40 copy number by ddPCR (2.50–5.47; cutoff 2.50), but all were confirmed as true CAH-X negative by Sanger-based testing.
- 42 of those 45 subjects (93.3%) carried at least one TNXA variant allele homologous to TNXB exon 40, defined by SNPs rs4959086(C>G) and rs77471377(C>G); the cohort-wide allele frequency was 10.3% (48/467).
- The TNXA variant was most often in cis with a normal CYP21A2 allele (22/48, 45.8%) or an In2G CYP21A2 allele (12/48, 25.0%); among chromosomes with known genotype, it was found on at least 13.3% (20/150) of normal CYP21A2 chromosomes and 11.8% (11/93) of In2G chromosomes.
- The authors report a masking example: a CAH carrier with CAH-X CH-1/normal genotype had TNXB exons 35 and 40 measured as one and two copies, respectively, because of a TNXB-like TNXA allele on the normal chromosome; they argue this could create false-negative CAH-X CH-2 calls.
## Methods
- The study used 278 subjects enrolled in an NIH Natural History Study (145 affected 21-OHD CAH patients, 116 carriers, 3 normal relatives, and 14 subjects/relatives with other diseases from 11 families).
- Copy numbers of TNXB exons 35 and 40, C4A, and C4B had been determined previously; TNXA copy number was inferred, and TNXA variants homologous to TNXB exon 40 were assessed by allele-specific PCR followed by Sanger sequencing.
- The main analysis compared ddPCR TNXB exon 40 copy-number results with sequencing and family genotype information to determine how often the TNXA variant co-occurred with CYP21A2 genotypes and whether it could interfere with CAH-X testing.
## Limitations
- The paper states that Sanger plus allele-specific PCR is accurate but low-throughput and constrained by difficult 8.5 kb long-range PCR across the RCCX locus.
- The authors note that they did not observe any true false-negative CAH-X calls in their cohort, so the masking risk is inferred from genotype patterns and one example rather than confirmed false-negative cases.
- Evident from the text: some TNXA variant alleles could not be phased to a CYP21A2 genotype because family genotype information was unavailable (7 TNXA variant alleles), limiting complete interpretation of cis associations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Schematic diagram of CAH and CAH-X chimeric genes [10]. (A), typical bimodular RCCX module: each pair of the homologous genes is shown in similar colors, with lighter colors representing pseudogenes; two RCCX units vulnerable for gene conversion are in brackets. (B), unequal crossover between CYP21A1P and CYP21A2, or TNXA and TNXB, results in a commonly termed “30-kb deletion” CAH genotype. (C), schemes of three major subtypes of “30-kb deletion”: top, CYP21A1P/CYP21A2 chimeric genes with intact TNXB, pathogenic for CAH; middle, CYP21A1P-TNXA/TNXB chimera CAH-X CH-1 with TNXB exons 35–44 replaced by TNXA causes CAH-X due to tenascin-X haploinsufficiency; bottom, CYP21A1P-TNXA/TNXB chimera CAH-X CH-2 with TNXB exons 40–44 replaced by TNXA causes CAH-X due to a dominant negative effect. CAH-X CH-1 has an exon 35 c.11435_11524+30 deletion (light green triangle) and an exon 40 c.12174C>G mutation (small black arrow) in tandem, whereas CAH-X CH-2 has an intact exon 35 (green triangle) and an exon 40 c.12174C>G mutation. The junction site window for each chimeric gene is shown in chameleonic colors. Schemes from CYP21A1P to TNXB intron 31, which is the boundary of RCCX module homologous repeats, are shown in scale. The size of TNXB is 68 kb.](https://figures.cochat.ai/paper-figures/5e74b137da0e466a9e3dc15cadd06e78/pseudogene-tnxa-variants-may-interfere-with-the-genetic-testing-of-cah-x-figure-1.jpg)
![Figure 2 Identification of CAH-X chimeric type by droplet digital PCR (ddPCR) [10]. The copy numbers of TNXB exons 35 and 40 determined by ddPCR were used for the call of CAH-X chimeric genes.](https://figures.cochat.ai/paper-figures/f967c5b8efbc493e8eb6f051572df4fc/pseudogene-tnxa-variants-may-interfere-with-the-genetic-testing-of-cah-x-figure-2.jpg)
Verification
Claims the paper makes
4 Valid · 0 Not valid · 0 Not checked · 21 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The two most common genetic causes of CAH-X are CYP21A1P-TNXA/TNXB chimeras with pseudogene TNXA substitution for TNXB exons 35–44 (CAH-X CH-1) and TNXB exons 40–44 (CAH-X CH-2).”
- Also stated in: § 1. Introduction · plain
“Two CAH-X chimeras account for the vast majority of CAH-X genotypes and also represent 30% of 30-kb deletions, or 15% of all CAH alleles: CAH-X CH-1 substitutes TNXA for TNXB exons 35–44, resulting in a null allele; while CAH-X CH-2 substitutes TNXA for TNXB exons 40–44, resulting in a dominant negative effect [8].”
§ Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X > Abstract
What the sources say
- Partly supportedcites [8] Morissette, 2015, Broadening the Spectrum of Ehlers Danlos Syndrome in Patients With Congenital Adrenal Hyperplasia, J. Clin. Endocrinol. Metab. sourceExperimental — accuracy not yet measured
The paper’s chimera description (indexed as Abstract; page unavailable) identifies CH-1 by a TNXA-derived deletion at exon 35 and CH-2 by a TNXA-derived variant in exon 40; its cohort reports 14 probands with the previously described chimera and seven with the novel variant. It describes exons 35–44 as TNXA-specific in CH-1, but does not establish substitution of all exons 40–44 in CH-2 or that these are the two most common causes of CAH-X generally. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One CAH carrier with CAH-X CH-1/normal genotype had her TNXB exons 35 and 40 copy numbers measured as one and two, respectively, which is different from a typical one copy each of the two TNXB exons in a monoallelic CAH-X CH-1. We found that a TNXB-like TNXA allele in her normal chromosome was the cause.”
§ Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X > 4. Discussion Large cohort studies of patients with CAH due to 21-OHD worldwide have revealed and confirmed that approximately 15% of CAH patients carry at least one CAH-X allele, a contiguous deletion disrupting both CYP21A2 and TNXB tandem genes [10,11,12,13]. Moreover, these deletions account for approximate 30% of chimeric genes, also termed 30-kb deletions. While CAH due to CYP21A2 defects is autosomal recessive, the hypermobile EDS connective tissue dysplasia due to TNXB defects appears to be autosomal dominant, as carrying one CAH-X allele has been associated with an EDS phenotype [7,8,10]. Other than typical joint and skin conditions, CAH-X patients have about 25% prevalence of cardiac abnormalities, including congenital heart defects, such as structural valve abnormalities, left ventricular diverticulum and patent foramen ovale [7,8]. A diagnosis of CAH-X is beneficial by offering awareness and early medical intervention if indicated, but traditional clinical diagnosis of CAH-X relying on joint hypermobility and subluxations is often restricted by factors such as age, and a reliable tenascin-X serum level assay is not available [34]. As an accurate and cost-effective option, we recently suggested the inclusion of CAH-X genotyping with the standard scope of CAH genetic tests, especially for individuals carrying a “30-kb deletion” genotype, given that a large portion (30%) of this genotype are in fact CAH-X chimeras [10]. We now describe potential interference with CAH-X molecular genetic testing based on copy number assessment due to a commonly found TNXA variant allele carrying a TNXB exon 40 sequence. The test and evaluation of CAH-X should also extend to CAH carriers who lack medical attention regarding CAH-related conditions [14,15,16]. Although hEDS manifestations are often milder compared to the CAH-X patient, carriers of a CAH-X allele are at risk of developing significant conditions, including a cardiac structural defect. In fact, since the classic CAH carrier prevalence is 1 in 60, about one third of CAH alleles are 30-kb deletions and one third of these are estimated to be CAH-X chimeras; CAH-X amongst CAH carriers alone is estimated to affect 1 in 670 in the general population. This coincides with a previous presumption that the 1 in 5000 prevalence of hEDS was grossly underestimated [25]. In order to include CAH-X chimeras into an existing CAH genetic test, Sanger sequencing followed by an allele-specific PCR with CYP779F/Tena32F primer pair remains the most accurate and comprehensive methodology. It is suitable for all conditions across the CYP21A2-TNXB exons 32–44 locus, and the test of CAH-X chimeras can be a simple add-on to the existing scope. However, this methodology is low-throughput and often restricted by a difficult 8.5 kb long-range PCR with frequent heterogeneous insert–deletions across the locus [32]. Clinical laboratories also use high-throughput methodologies, such as quantitative PCR, multiplex mini-sequencing, conversion-specific PCR (MMCP) and multiplex ligation-dependent probe amplification (MLPA), to conduct CAH genetic testing [14,35,36]. Among these methodologies, only the MLPA platform tests the TNXB exon 35 copy number that can be used for calling CAH-X CH-1, but TNXB exon 40 is completely out of scope. In order to evaluate TNXB status, our recently developed ddPCR-based assay may be added to these CAH methodologies. Alternatively, new assays amenable to existing platforms could be developed, but in either case, the potential influence of the pseudogene TNXA homologue should be considered. In our previous work of developing a high-throughput CAH-X screening assay based on TNXB copy number losses, we observed that a large portion of true CAH-X negative samples (45/234) had an excessive TNXB exon 40 copy number (≥2.5) as measured by ddPCR [10]. We previously hypothesized that this was likely caused by a TNXA variant allele carrying SNPs rs77471377(C>G) and rs4959086(C>G) in tandem, which converted the locus to be TNXB-like, and thus detectable by the ddPCR assay. This TNXA variant allele was, in fact, commonly found in our CAH cohort. Although it remains as a pseudogene without affecting phenotypic outcomes, this TNXB-like TNXA variant allele may interfere genetic tests of CAH-X based on TNXB copy number assessment. For example, when a subject carries a CAH-X CH-2 chimera with at least one copy of this TNXA variant, the real TNXB exon 40 copy number loss will be masked by the latter’s homologue, creating an inevitable risk of a false negative call on CAH-X CH-2. In our large CAH cohort, 31 out of 135 21-OHD CAH families and 6 out of 11 families with other conditions carried such a TNXB-like TNXA allele, suggesting this threat of false negative CAH-X CH-2 determinations might commonly exist. However, we did not record any false negative cases in the assessment of all 278 subjects in our cohort. One explanation could be that no such TNXA variant was found in cis with any of the CAH 30-kb deletion genotypes. Since CAH-X alleles are mostly TNXA-free, with mono-modular RCCX structure, this might significantly reduce the possibility of TNXA-sourced interferences. On the other hand, masking interference from the in trans chromosome warrants consideration. The majority of TNXB-like TNXA variants were in cis with either a normal or an In2G CYP21A2 allele. Accordingly, CAH carriers with a CAH-X CH-2/normal genotype and CAH patients with a CAH-X CH-2/In2G genotype are more likely than other genotypes to encounter a false negative call. Theoretically, this chance is approximately 10%, given that the prevalence of this TNXA variant allele amongst chromosomes of normal and In2G CYP21A2 was 13.3% and 11.8%, respectively. Although we did not have a true false negative call in our cohort, we did have an example of masking interference from the in trans chromosome (Figure 2, the outlier red dot). One CAH carrier with CAH-X CH-1/normal genotype had her TNXB exons 35 and 40 copy numbers measured as one and two, respectively, which is different from a typical one copy each of the two TNXB exons in a monoallelic CAH-X CH-1. We found that a TNXB-like TNXA allele in her normal chromosome was the cause. This would have been a case of false negative call if she had carried a CAH-X CH-2 allele instead of CAH-X CH-1, whose loss in TNXB exon 35 copy number alone warranted a correct call [10]. In the genetics of 21-OHD CAH, a minor conversion is defined as a small portion of the pseudogene CYP21A1P being converted to CYP21A2 to cause pathogenic defects, which include the 10 most common variants [3,14]. These variants have been well investigated and are currently within the scope of all standard CAH test platforms [14]. On the other hand, gene conversion in the opposite direction, from CYP21A2 to CYP21A1P, has only been documented in a few studies. Cantürk, C. et al. reported that 8.5% of CYP21A1P alleles are CYP21A2-like at the position corresponding to p.I172, which might be mistaken for a CYP21A2 duplication when using MLPA methodology [37]. Tsai, L. et al. reported that CYP21A2-like spots were commonly found throughout CYP21A1P, such as p.P30, p.G110, p.I172, p.V281, p.Q318 and p.R356 [38,39,40]. Notably, these reports were all based on healthy non-CAH populations. Although these prior reports suggested potential pseudogene interference with CYP21A2 genotyping, the true frequency or significance of this interference has not yet been established due to the lack of studies using large CAH cohorts. In our current study, we reveal that real-gene-like spots also exist in pseudogene TNXA, or in at least a locus corresponding to TNXB exon 40. This TNXB-like TNXA variant might cause a false negative call on CAH-X CH-2 if using high-throughput methods such as ddPCR. Our findings provide noteworthy insight into the nature and complexity of the RCCX modules. Finally, our findings support the concept that standard NGS-based methodologies are not yet suitable for the genetic testing of RCCX module genes within the homologous window, not only for CYP21A2 but also for TNXB exons 32–44 [14,31,41]. Mainstream population-based databases using NGS methodologies, such as the gnomAD browser, lists allele frequency of the two SNPs of this study to be 0.1795 for rs4959086(C>G) and 0.02 for rs77471377(C>G) [42]. However, since the copy number of TNXA varies from 0–4 in each chromosome, the classical calculation of allele frequency based on two alleles in each subject is not accurate. In fact, there were a total of 467 TNXA alleles in our cohort of 278 subjects; thus, an allele frequency of the TNXA variant haplotype with both SNPs in tandem was 10.3% (48/467), suggesting an underestimation of rs7741377(C>G) allele frequency in the CAH population. One may argue that findings could be different in the general population; we therefore also evaluated the frequency of TNXA variant haplotype exclusively amongst the “normal” non-CAH chromosomes in our cohort. Because the TNXA copy number was determined in diploid, while haploid-specific copy number was not available in all subjects, our next frequency calculation was based on “chromosome” rather than “allele”. There were a total of 150 normal chromosomes in our cohort; at least 20 of them carried one or more copies of the TNXA variant haplotype, and therefore the chromosome-based frequency should be approximately 13.3% (20/150), which again agreed with our prediction of an underestimated rs7741377(C>G) allele frequency. In either case, our results suggested that the real-gene-like variants throughout pseudogenes CYP21A1P and TNXA, as well as their underestimated allele frequency, should be considered as another obstacle to overcome in addition to the commonly accepted pseudogene homologue and copy number variations in terms of designing a comprehensive CAH test platform based on NGS methodologies.
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were a total of 467 TNXA alleles in the entire cohort; therefore, the allele frequency of the TNXA variant allele responsible for the excessive ddPCR TNXB exon 40 copy number was 10.3% (48/467).”
- Also stated in: § 4. Discussion Large cohort studies of patients with CAH due to 21-OHD worldwide have revealed and confirmed that approximately 15% of CAH patients carry at least one CAH-X allele, a contiguous deletion disrupting both CYP21A2 and TNXB tandem genes [10,11,12,13]. Moreover, these deletions account for approximate 30% of chimeric genes, also termed 30-kb deletions. While CAH due to CYP21A2 defects is autosomal recessive, the hypermobile EDS connective tissue dysplasia due to TNXB defects appears to be autosomal dominant, as carrying one CAH-X allele has been associated with an EDS phenotype [7,8,10]. Other than typical joint and skin conditions, CAH-X patients have about 25% prevalence of cardiac abnormalities, including congenital heart defects, such as structural valve abnormalities, left ventricular diverticulum and patent foramen ovale [7,8]. A diagnosis of CAH-X is beneficial by offering awareness and early medical intervention if indicated, but traditional clinical diagnosis of CAH-X relying on joint hypermobility and subluxations is often restricted by factors such as age, and a reliable tenascin-X serum level assay is not available [34]. As an accurate and cost-effective option, we recently suggested the inclusion of CAH-X genotyping with the standard scope of CAH genetic tests, especially for individuals carrying a “30-kb deletion” genotype, given that a large portion (30%) of this genotype are in fact CAH-X chimeras [10]. We now describe potential interference with CAH-X molecular genetic testing based on copy number assessment due to a commonly found TNXA variant allele carrying a TNXB exon 40 sequence. The test and evaluation of CAH-X should also extend to CAH carriers who lack medical attention regarding CAH-related conditions [14,15,16]. Although hEDS manifestations are often milder compared to the CAH-X patient, carriers of a CAH-X allele are at risk of developing significant conditions, including a cardiac structural defect. In fact, since the classic CAH carrier prevalence is 1 in 60, about one third of CAH alleles are 30-kb deletions and one third of these are estimated to be CAH-X chimeras; CAH-X amongst CAH carriers alone is estimated to affect 1 in 670 in the general population. This coincides with a previous presumption that the 1 in 5000 prevalence of hEDS was grossly underestimated [25]. In order to include CAH-X chimeras into an existing CAH genetic test, Sanger sequencing followed by an allele-specific PCR with CYP779F/Tena32F primer pair remains the most accurate and comprehensive methodology. It is suitable for all conditions across the CYP21A2-TNXB exons 32–44 locus, and the test of CAH-X chimeras can be a simple add-on to the existing scope. However, this methodology is low-throughput and often restricted by a difficult 8.5 kb long-range PCR with frequent heterogeneous insert–deletions across the locus [32]. Clinical laboratories also use high-throughput methodologies, such as quantitative PCR, multiplex mini-sequencing, conversion-specific PCR (MMCP) and multiplex ligation-dependent probe amplification (MLPA), to conduct CAH genetic testing [14,35,36]. Among these methodologies, only the MLPA platform tests the TNXB exon 35 copy number that can be used for calling CAH-X CH-1, but TNXB exon 40 is completely out of scope. In order to evaluate TNXB status, our recently developed ddPCR-based assay may be added to these CAH methodologies. Alternatively, new assays amenable to existing platforms could be developed, but in either case, the potential influence of the pseudogene TNXA homologue should be considered. In our previous work of developing a high-throughput CAH-X screening assay based on TNXB copy number losses, we observed that a large portion of true CAH-X negative samples (45/234) had an excessive TNXB exon 40 copy number (≥2.5) as measured by ddPCR [10]. We previously hypothesized that this was likely caused by a TNXA variant allele carrying SNPs rs77471377(C>G) and rs4959086(C>G) in tandem, which converted the locus to be TNXB-like, and thus detectable by the ddPCR assay. This TNXA variant allele was, in fact, commonly found in our CAH cohort. Although it remains as a pseudogene without affecting phenotypic outcomes, this TNXB-like TNXA variant allele may interfere genetic tests of CAH-X based on TNXB copy number assessment. For example, when a subject carries a CAH-X CH-2 chimera with at least one copy of this TNXA variant, the real TNXB exon 40 copy number loss will be masked by the latter’s homologue, creating an inevitable risk of a false negative call on CAH-X CH-2. In our large CAH cohort, 31 out of 135 21-OHD CAH families and 6 out of 11 families with other conditions carried such a TNXB-like TNXA allele, suggesting this threat of false negative CAH-X CH-2 determinations might commonly exist. However, we did not record any false negative cases in the assessment of all 278 subjects in our cohort. One explanation could be that no such TNXA variant was found in cis with any of the CAH 30-kb deletion genotypes. Since CAH-X alleles are mostly TNXA-free, with mono-modular RCCX structure, this might significantly reduce the possibility of TNXA-sourced interferences. On the other hand, masking interference from the in trans chromosome warrants consideration. The majority of TNXB-like TNXA variants were in cis with either a normal or an In2G CYP21A2 allele. Accordingly, CAH carriers with a CAH-X CH-2/normal genotype and CAH patients with a CAH-X CH-2/In2G genotype are more likely than other genotypes to encounter a false negative call. Theoretically, this chance is approximately 10%, given that the prevalence of this TNXA variant allele amongst chromosomes of normal and In2G CYP21A2 was 13.3% and 11.8%, respectively. Although we did not have a true false negative call in our cohort, we did have an example of masking interference from the in trans chromosome (Figure 2, the outlier red dot). One CAH carrier with CAH-X CH-1/normal genotype had her TNXB exons 35 and 40 copy numbers measured as one and two, respectively, which is different from a typical one copy each of the two TNXB exons in a monoallelic CAH-X CH-1. We found that a TNXB-like TNXA allele in her normal chromosome was the cause. This would have been a case of false negative call if she had carried a CAH-X CH-2 allele instead of CAH-X CH-1, whose loss in TNXB exon 35 copy number alone warranted a correct call [10]. In the genetics of 21-OHD CAH, a minor conversion is defined as a small portion of the pseudogene CYP21A1P being converted to CYP21A2 to cause pathogenic defects, which include the 10 most common variants [3,14]. These variants have been well investigated and are currently within the scope of all standard CAH test platforms [14]. On the other hand, gene conversion in the opposite direction, from CYP21A2 to CYP21A1P, has only been documented in a few studies. Cantürk, C. et al. reported that 8.5% of CYP21A1P alleles are CYP21A2-like at the position corresponding to p.I172, which might be mistaken for a CYP21A2 duplication when using MLPA methodology [37]. Tsai, L. et al. reported that CYP21A2-like spots were commonly found throughout CYP21A1P, such as p.P30, p.G110, p.I172, p.V281, p.Q318 and p.R356 [38,39,40]. Notably, these reports were all based on healthy non-CAH populations. Although these prior reports suggested potential pseudogene interference with CYP21A2 genotyping, the true frequency or significance of this interference has not yet been established due to the lack of studies using large CAH cohorts. In our current study, we reveal that real-gene-like spots also exist in pseudogene TNXA, or in at least a locus corresponding to TNXB exon 40. This TNXB-like TNXA variant might cause a false negative call on CAH-X CH-2 if using high-throughput methods such as ddPCR. Our findings provide noteworthy insight into the nature and complexity of the RCCX modules. Finally, our findings support the concept that standard NGS-based methodologies are not yet suitable for the genetic testing of RCCX module genes within the homologous window, not only for CYP21A2 but also for TNXB exons 32–44 [14,31,41]. Mainstream population-based databases using NGS methodologies, such as the gnomAD browser, lists allele frequency of the two SNPs of this study to be 0.1795 for rs4959086(C>G) and 0.02 for rs77471377(C>G) [42]. However, since the copy number of TNXA varies from 0–4 in each chromosome, the classical calculation of allele frequency based on two alleles in each subject is not accurate. In fact, there were a total of 467 TNXA alleles in our cohort of 278 subjects; thus, an allele frequency of the TNXA variant haplotype with both SNPs in tandem was 10.3% (48/467), suggesting an underestimation of rs7741377(C>G) allele frequency in the CAH population. One may argue that findings could be different in the general population; we therefore also evaluated the frequency of TNXA variant haplotype exclusively amongst the “normal” non-CAH chromosomes in our cohort. Because the TNXA copy number was determined in diploid, while haploid-specific copy number was not available in all subjects, our next frequency calculation was based on “chromosome” rather than “allele”. There were a total of 150 normal chromosomes in our cohort; at least 20 of them carried one or more copies of the TNXA variant haplotype, and therefore the chromosome-based frequency should be approximately 13.3% (20/150), which again agreed with our prediction of an underestimated rs7741377(C>G) allele frequency. In either case, our results suggested that the real-gene-like variants throughout pseudogenes CYP21A1P and TNXA, as well as their underestimated allele frequency, should be considered as another obstacle to overcome in addition to the commonly accepted pseudogene homologue and copy number variations in terms of designing a comprehensive CAH test platform based on NGS methodologies. · plain
“In fact, there were a total of 467 TNXA alleles in our cohort of 278 subjects; thus, an allele frequency of the TNXA variant haplotype with both SNPs in tandem was 10.3% (48/467), suggesting an underestimation of rs7741377(C>G) allele frequency in the CAH population.”
§ Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X > 3. Results Amongst the 278 subjects who underwent CAH-X screening, 45 of them from 37 unrelated families (31 with 21-OHD and 6 others) had an excessive copy number of TNXB exon 40 (2.50–5.47, with 2.50 as the cutoff value) as measured by the digital droplet PCR assay. These 45 subjects were all confirmed as true CAH-X negative with a Sanger-based methodology conducted by a CLIA-accredited laboratory (PreventionGenetics, LLC, Marshfield, WI, USA). Their disease conditions included 18 patients with 21-OHD CAH (9 salt-wasting, 8 simple virilizing and 1 nonclassic), 18 carriers of 21-OHD CAH, 3 unaffected relatives of 21-OH CAH and 6 relatives of subjects with other endocrine conditions (Table 1). Forty-two subjects (93.3%, 42/45) had at least one allele of a TNXA variant homologous to the TNXB exon 40 by carrying SNPs rs4959086(C>G) and rs77471377(C>G), forty-one of them with both SNPs in tandem and one subject with rs77471377(C>G) alone. A total of 48 TNXB-exon 40-like TNXA variant alleles were detected in these 42 subjects. All 278 subjects of the cohort had previously measured C4A and C4B copy numbers by which their respective RCCX module unit numbers were determined [33]; accordingly, their respective TNXA copy numbers were also determined. There were a total of 467 TNXA alleles in the entire cohort; therefore, the allele frequency of the TNXA variant allele responsible for the excessive ddPCR TNXB exon 40 copy number was 10.3% (48/467). Amongst the 11 subjects carrying one copy of TNXA, 10 had the TNXB-like variant as their lone TNXA allele. Amongst the 27 subjects carrying two copies of TNXA, 3 had both copies and 23 had one copy as the TNXB-like variant. Amongst the seven subjects carrying three copies of TNXA, one had all three copies, one had two copies and four had one copy as the TNXB-like TNXA variant. The two SNPs were determined as in cis in all heterozygous cases by either family genotyping or TA clone sequencing, reflecting the ddPCR methodology which detects SNPs in tandem. As a control group, twenty-nine subjects confirmed negative for CAH-X and a normal range TNXB exon 40 copy number (1.7–2.4) were tested on the TNXA locus of interest. No SNP rs77471377(C>G) was detected in this group, whereas four carried a heterozygous rs4959086(C>G). Hence, this TNXB-like TNXA variant allele was indeed the predominant cause of the excessive TNXB exon 40 copy number measured by ddPCR. It was found most frequently in cis with a normal CYP21A2 allele, with 22 out of 48 alleles, or 45.8% in cis with 21 (or 20) normal CYP21A2 alleles in 19 subjects from 17 families. The second most frequent in cis CYP21A2 genotype was In2G; 12 (25.0%, 12/48) of the TNXA variant alleles shared a chromosome with 11 CYP21A2 In2G alleles in 10 subjects from six families. Other findings included: two families had a TNXA variant allele in cis with a CYP21A2 Q318X allele; one family each had a TNXA variant in cis with a CYP21A2 I172N, del-I172N and IV8 + 1G>A allele, respectively. We failed to determine the in cis CYP21A2 association of seven TNXA variant alleles due to absence of family genotype information. Thus, based on the 150 chromosomes with known normal CYP21A2 and the 93 chromosomes of In2G CYP21A2 (55 patients with 21-OHD CAH and 24 carriers) in our cohort, we found that at least 13.3% (20/150) and 11.8% (11/93) of unaffected and In2G CYP21A2 alleles shared a chromosome with one or more copies of this TNXA variant allele, respectively. Three subjects with excessive ddPCR TNXB exon 40 copy number did not have a detectable TNXB-like TNXA allele, as shown in Table 1. Subject 25A had her TNXB exon 40 copy number measured as 2.62; she had one copy of TNXA determined as wild-type which matched the reference genome in this study, thus the mechanism underlying the excessive 0.62 copy of TNXB exon 40 remains unclear. Subject 33 had the TNXB exon 40 copy number measured as 2.87; two wild-type copies of TNXA were present. This was the lone case of TNXB exon 35 being measured as 2.83 (Figure 2) without further evidence of structural variation in the loci; thus, the excessive copy numbers were likely due to some variants in the HBB gene whose copy number was used to normalize the TNXB exons in the ddPCR assays. Subject 27B had 2.92 copies of TNXB exon 40 measured by ddPCR with 3 copies of TNXA, but our PCR protocol repeatedly failed to amplify these loci, leaving the mechanism unknown.
plainn = 278- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 4. Discussion Large cohort studies of patients with CAH due to 21-OHD worldwide have revealed and confirmed that approximately 15% of CAH patients carry at least one CAH-X allele, a contiguous deletion disrupting both CYP21A2 and TNXB tandem genes [10,11,12,13]. Moreover, these deletions account for approximate 30% of chimeric genes, also termed 30-kb deletions. While CAH due to CYP21A2 defects is autosomal recessive, the hypermobile EDS connective tissue dysplasia due to TNXB defects appears to be autosomal dominant, as carrying one CAH-X allele has been associated with an EDS phenotype [7,8,10]. Other than typical joint and skin conditions, CAH-X patients have about 25% prevalence of cardiac abnormalities, including congenital heart defects, such as structural valve abnormalities, left ventricular diverticulum and patent foramen ovale [7,8]. A diagnosis of CAH-X is beneficial by offering awareness and early medical intervention if indicated, but traditional clinical diagnosis of CAH-X relying on joint hypermobility and subluxations is often restricted by factors such as age, and a reliable tenascin-X serum level assay is not available [34]. As an accurate and cost-effective option, we recently suggested the inclusion of CAH-X genotyping with the standard scope of CAH genetic tests, especially for individuals carrying a “30-kb deletion” genotype, given that a large portion (30%) of this genotype are in fact CAH-X chimeras [10]. We now describe potential interference with CAH-X molecular genetic testing based on copy number assessment due to a commonly found TNXA variant allele carrying a TNXB exon 40 sequence. The test and evaluation of CAH-X should also extend to CAH carriers who lack medical attention regarding CAH-related conditions [14,15,16]. Although hEDS manifestations are often milder compared to the CAH-X patient, carriers of a CAH-X allele are at risk of developing significant conditions, including a cardiac structural defect. In fact, since the classic CAH carrier prevalence is 1 in 60, about one third of CAH alleles are 30-kb deletions and one third of these are estimated to be CAH-X chimeras; CAH-X amongst CAH carriers alone is estimated to affect 1 in 670 in the general population. This coincides with a previous presumption that the 1 in 5000 prevalence of hEDS was grossly underestimated [25]. In order to include CAH-X chimeras into an existing CAH genetic test, Sanger sequencing followed by an allele-specific PCR with CYP779F/Tena32F primer pair remains the most accurate and comprehensive methodology. It is suitable for all conditions across the CYP21A2-TNXB exons 32–44 locus, and the test of CAH-X chimeras can be a simple add-on to the existing scope. However, this methodology is low-throughput and often restricted by a difficult 8.5 kb long-range PCR with frequent heterogeneous insert–deletions across the locus [32]. Clinical laboratories also use high-throughput methodologies, such as quantitative PCR, multiplex mini-sequencing, conversion-specific PCR (MMCP) and multiplex ligation-dependent probe amplification (MLPA), to conduct CAH genetic testing [14,35,36]. Among these methodologies, only the MLPA platform tests the TNXB exon 35 copy number that can be used for calling CAH-X CH-1, but TNXB exon 40 is completely out of scope. In order to evaluate TNXB status, our recently developed ddPCR-based assay may be added to these CAH methodologies. Alternatively, new assays amenable to existing platforms could be developed, but in either case, the potential influence of the pseudogene TNXA homologue should be considered. In our previous work of developing a high-throughput CAH-X screening assay based on TNXB copy number losses, we observed that a large portion of true CAH-X negative samples (45/234) had an excessive TNXB exon 40 copy number (≥2.5) as measured by ddPCR [10]. We previously hypothesized that this was likely caused by a TNXA variant allele carrying SNPs rs77471377(C>G) and rs4959086(C>G) in tandem, which converted the locus to be TNXB-like, and thus detectable by the ddPCR assay. This TNXA variant allele was, in fact, commonly found in our CAH cohort. Although it remains as a pseudogene without affecting phenotypic outcomes, this TNXB-like TNXA variant allele may interfere genetic tests of CAH-X based on TNXB copy number assessment. For example, when a subject carries a CAH-X CH-2 chimera with at least one copy of this TNXA variant, the real TNXB exon 40 copy number loss will be masked by the latter’s homologue, creating an inevitable risk of a false negative call on CAH-X CH-2. In our large CAH cohort, 31 out of 135 21-OHD CAH families and 6 out of 11 families with other conditions carried such a TNXB-like TNXA allele, suggesting this threat of false negative CAH-X CH-2 determinations might commonly exist. However, we did not record any false negative cases in the assessment of all 278 subjects in our cohort. One explanation could be that no such TNXA variant was found in cis with any of the CAH 30-kb deletion genotypes. Since CAH-X alleles are mostly TNXA-free, with mono-modular RCCX structure, this might significantly reduce the possibility of TNXA-sourced interferences. On the other hand, masking interference from the in trans chromosome warrants consideration. The majority of TNXB-like TNXA variants were in cis with either a normal or an In2G CYP21A2 allele. Accordingly, CAH carriers with a CAH-X CH-2/normal genotype and CAH patients with a CAH-X CH-2/In2G genotype are more likely than other genotypes to encounter a false negative call. Theoretically, this chance is approximately 10%, given that the prevalence of this TNXA variant allele amongst chromosomes of normal and In2G CYP21A2 was 13.3% and 11.8%, respectively. Although we did not have a true false negative call in our cohort, we did have an example of masking interference from the in trans chromosome (Figure 2, the outlier red dot). One CAH carrier with CAH-X CH-1/normal genotype had her TNXB exons 35 and 40 copy numbers measured as one and two, respectively, which is different from a typical one copy each of the two TNXB exons in a monoallelic CAH-X CH-1. We found that a TNXB-like TNXA allele in her normal chromosome was the cause. This would have been a case of false negative call if she had carried a CAH-X CH-2 allele instead of CAH-X CH-1, whose loss in TNXB exon 35 copy number alone warranted a correct call [10]. In the genetics of 21-OHD CAH, a minor conversion is defined as a small portion of the pseudogene CYP21A1P being converted to CYP21A2 to cause pathogenic defects, which include the 10 most common variants [3,14]. These variants have been well investigated and are currently within the scope of all standard CAH test platforms [14]. On the other hand, gene conversion in the opposite direction, from CYP21A2 to CYP21A1P, has only been documented in a few studies. Cantürk, C. et al. reported that 8.5% of CYP21A1P alleles are CYP21A2-like at the position corresponding to p.I172, which might be mistaken for a CYP21A2 duplication when using MLPA methodology [37]. Tsai, L. et al. reported that CYP21A2-like spots were commonly found throughout CYP21A1P, such as p.P30, p.G110, p.I172, p.V281, p.Q318 and p.R356 [38,39,40]. Notably, these reports were all based on healthy non-CAH populations. Although these prior reports suggested potential pseudogene interference with CYP21A2 genotyping, the true frequency or significance of this interference has not yet been established due to the lack of studies using large CAH cohorts. In our current study, we reveal that real-gene-like spots also exist in pseudogene TNXA, or in at least a locus corresponding to TNXB exon 40. This TNXB-like TNXA variant might cause a false negative call on CAH-X CH-2 if using high-throughput methods such as ddPCR. Our findings provide noteworthy insight into the nature and complexity of the RCCX modules. Finally, our findings support the concept that standard NGS-based methodologies are not yet suitable for the genetic testing of RCCX module genes within the homologous window, not only for CYP21A2 but also for TNXB exons 32–44 [14,31,41]. Mainstream population-based databases using NGS methodologies, such as the gnomAD browser, lists allele frequency of the two SNPs of this study to be 0.1795 for rs4959086(C>G) and 0.02 for rs77471377(C>G) [42]. However, since the copy number of TNXA varies from 0–4 in each chromosome, the classical calculation of allele frequency based on two alleles in each subject is not accurate. In fact, there were a total of 467 TNXA alleles in our cohort of 278 subjects; thus, an allele frequency of the TNXA variant haplotype with both SNPs in tandem was 10.3% (48/467), suggesting an underestimation of rs7741377(C>G) allele frequency in the CAH population. One may argue that findings could be different in the general population; we therefore also evaluated the frequency of TNXA variant haplotype exclusively amongst the “normal” non-CAH chromosomes in our cohort. Because the TNXA copy number was determined in diploid, while haploid-specific copy number was not available in all subjects, our next frequency calculation was based on “chromosome” rather than “allele”. There were a total of 150 normal chromosomes in our cohort; at least 20 of them carried one or more copies of the TNXA variant haplotype, and therefore the chromosome-based frequency should be approximately 13.3% (20/150), which again agreed with our prediction of an underestimated rs7741377(C>G) allele frequency. In either case, our results suggested that the real-gene-like variants throughout pseudogenes CYP21A1P and TNXA, as well as their underestimated allele frequency, should be considered as another obstacle to overcome in addition to the commonly accepted pseudogene homologue and copy number variations in terms of designing a comprehensive CAH test platform based on NGS methodologies. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 45 subjects (40 families) from a cohort of 278 subjects (135 families of 21-OHD and 11 families of other conditions) were found to have excessive TNXB exon 40 copy number as measured by digital PCR.”
- Also stated in: § 3. Results Amongst the 278 subjects who underwent CAH-X screening, 45 of them from 37 unrelated families (31 with 21-OHD and 6 others) had an excessive copy number of TNXB exon 40 (2.50–5.47, with 2.50 as the cutoff value) as measured by the digital droplet PCR assay. These 45 subjects were all confirmed as true CAH-X negative with a Sanger-based methodology conducted by a CLIA-accredited laboratory (PreventionGenetics, LLC, Marshfield, WI, USA). Their disease conditions included 18 patients with 21-OHD CAH (9 salt-wasting, 8 simple virilizing and 1 nonclassic), 18 carriers of 21-OHD CAH, 3 unaffected relatives of 21-OH CAH and 6 relatives of subjects with other endocrine conditions (Table 1). Forty-two subjects (93.3%, 42/45) had at least one allele of a TNXA variant homologous to the TNXB exon 40 by carrying SNPs rs4959086(C>G) and rs77471377(C>G), forty-one of them with both SNPs in tandem and one subject with rs77471377(C>G) alone. A total of 48 TNXB-exon 40-like TNXA variant alleles were detected in these 42 subjects. All 278 subjects of the cohort had previously measured C4A and C4B copy numbers by which their respective RCCX module unit numbers were determined [33]; accordingly, their respective TNXA copy numbers were also determined. There were a total of 467 TNXA alleles in the entire cohort; therefore, the allele frequency of the TNXA variant allele responsible for the excessive ddPCR TNXB exon 40 copy number was 10.3% (48/467). Amongst the 11 subjects carrying one copy of TNXA, 10 had the TNXB-like variant as their lone TNXA allele. Amongst the 27 subjects carrying two copies of TNXA, 3 had both copies and 23 had one copy as the TNXB-like variant. Amongst the seven subjects carrying three copies of TNXA, one had all three copies, one had two copies and four had one copy as the TNXB-like TNXA variant. The two SNPs were determined as in cis in all heterozygous cases by either family genotyping or TA clone sequencing, reflecting the ddPCR methodology which detects SNPs in tandem. As a control group, twenty-nine subjects confirmed negative for CAH-X and a normal range TNXB exon 40 copy number (1.7–2.4) were tested on the TNXA locus of interest. No SNP rs77471377(C>G) was detected in this group, whereas four carried a heterozygous rs4959086(C>G). Hence, this TNXB-like TNXA variant allele was indeed the predominant cause of the excessive TNXB exon 40 copy number measured by ddPCR. It was found most frequently in cis with a normal CYP21A2 allele, with 22 out of 48 alleles, or 45.8% in cis with 21 (or 20) normal CYP21A2 alleles in 19 subjects from 17 families. The second most frequent in cis CYP21A2 genotype was In2G; 12 (25.0%, 12/48) of the TNXA variant alleles shared a chromosome with 11 CYP21A2 In2G alleles in 10 subjects from six families. Other findings included: two families had a TNXA variant allele in cis with a CYP21A2 Q318X allele; one family each had a TNXA variant in cis with a CYP21A2 I172N, del-I172N and IV8 + 1G>A allele, respectively. We failed to determine the in cis CYP21A2 association of seven TNXA variant alleles due to absence of family genotype information. Thus, based on the 150 chromosomes with known normal CYP21A2 and the 93 chromosomes of In2G CYP21A2 (55 patients with 21-OHD CAH and 24 carriers) in our cohort, we found that at least 13.3% (20/150) and 11.8% (11/93) of unaffected and In2G CYP21A2 alleles shared a chromosome with one or more copies of this TNXA variant allele, respectively. Three subjects with excessive ddPCR TNXB exon 40 copy number did not have a detectable TNXB-like TNXA allele, as shown in Table 1. Subject 25A had her TNXB exon 40 copy number measured as 2.62; she had one copy of TNXA determined as wild-type which matched the reference genome in this study, thus the mechanism underlying the excessive 0.62 copy of TNXB exon 40 remains unclear. Subject 33 had the TNXB exon 40 copy number measured as 2.87; two wild-type copies of TNXA were present. This was the lone case of TNXB exon 35 being measured as 2.83 (Figure 2) without further evidence of structural variation in the loci; thus, the excessive copy numbers were likely due to some variants in the HBB gene whose copy number was used to normalize the TNXB exons in the ddPCR assays. Subject 27B had 2.92 copies of TNXB exon 40 measured by ddPCR with 3 copies of TNXA, but our PCR protocol repeatedly failed to amplify these loci, leaving the mechanism unknown. · plain
“Amongst the 278 subjects who underwent CAH-X screening, 45 of them from 37 unrelated families (31 with 21-OHD and 6 others) had an excessive copy number of TNXB exon 40 (2.50–5.47, with 2.50 as the cutoff value) as measured by the digital droplet PCR assay.”
§ Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X > Abstract
plainn = 45- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 3. Results Amongst the 278 subjects who underwent CAH-X screening, 45 of them from 37 unrelated families (31 with 21-OHD and 6 others) had an excessive copy number of TNXB exon 40 (2.50–5.47, with 2.50 as the cutoff value) as measured by the digital droplet PCR assay. These 45 subjects were all confirmed as true CAH-X negative with a Sanger-based methodology conducted by a CLIA-accredited laboratory (PreventionGenetics, LLC, Marshfield, WI, USA). Their disease conditions included 18 patients with 21-OHD CAH (9 salt-wasting, 8 simple virilizing and 1 nonclassic), 18 carriers of 21-OHD CAH, 3 unaffected relatives of 21-OH CAH and 6 relatives of subjects with other endocrine conditions (Table 1). Forty-two subjects (93.3%, 42/45) had at least one allele of a TNXA variant homologous to the TNXB exon 40 by carrying SNPs rs4959086(C>G) and rs77471377(C>G), forty-one of them with both SNPs in tandem and one subject with rs77471377(C>G) alone. A total of 48 TNXB-exon 40-like TNXA variant alleles were detected in these 42 subjects. All 278 subjects of the cohort had previously measured C4A and C4B copy numbers by which their respective RCCX module unit numbers were determined [33]; accordingly, their respective TNXA copy numbers were also determined. There were a total of 467 TNXA alleles in the entire cohort; therefore, the allele frequency of the TNXA variant allele responsible for the excessive ddPCR TNXB exon 40 copy number was 10.3% (48/467). Amongst the 11 subjects carrying one copy of TNXA, 10 had the TNXB-like variant as their lone TNXA allele. Amongst the 27 subjects carrying two copies of TNXA, 3 had both copies and 23 had one copy as the TNXB-like variant. Amongst the seven subjects carrying three copies of TNXA, one had all three copies, one had two copies and four had one copy as the TNXB-like TNXA variant. The two SNPs were determined as in cis in all heterozygous cases by either family genotyping or TA clone sequencing, reflecting the ddPCR methodology which detects SNPs in tandem. As a control group, twenty-nine subjects confirmed negative for CAH-X and a normal range TNXB exon 40 copy number (1.7–2.4) were tested on the TNXA locus of interest. No SNP rs77471377(C>G) was detected in this group, whereas four carried a heterozygous rs4959086(C>G). Hence, this TNXB-like TNXA variant allele was indeed the predominant cause of the excessive TNXB exon 40 copy number measured by ddPCR. It was found most frequently in cis with a normal CYP21A2 allele, with 22 out of 48 alleles, or 45.8% in cis with 21 (or 20) normal CYP21A2 alleles in 19 subjects from 17 families. The second most frequent in cis CYP21A2 genotype was In2G; 12 (25.0%, 12/48) of the TNXA variant alleles shared a chromosome with 11 CYP21A2 In2G alleles in 10 subjects from six families. Other findings included: two families had a TNXA variant allele in cis with a CYP21A2 Q318X allele; one family each had a TNXA variant in cis with a CYP21A2 I172N, del-I172N and IV8 + 1G>A allele, respectively. We failed to determine the in cis CYP21A2 association of seven TNXA variant alleles due to absence of family genotype information. Thus, based on the 150 chromosomes with known normal CYP21A2 and the 93 chromosomes of In2G CYP21A2 (55 patients with 21-OHD CAH and 24 carriers) in our cohort, we found that at least 13.3% (20/150) and 11.8% (11/93) of unaffected and In2G CYP21A2 alleles shared a chromosome with one or more copies of this TNXA variant allele, respectively. Three subjects with excessive ddPCR TNXB exon 40 copy number did not have a detectable TNXB-like TNXA allele, as shown in Table 1. Subject 25A had her TNXB exon 40 copy number measured as 2.62; she had one copy of TNXA determined as wild-type which matched the reference genome in this study, thus the mechanism underlying the excessive 0.62 copy of TNXB exon 40 remains unclear. Subject 33 had the TNXB exon 40 copy number measured as 2.87; two wild-type copies of TNXA were present. This was the lone case of TNXB exon 35 being measured as 2.83 (Figure 2) without further evidence of structural variation in the loci; thus, the excessive copy numbers were likely due to some variants in the HBB gene whose copy number was used to normalize the TNXB exons in the ddPCR assays. Subject 27B had 2.92 copies of TNXB exon 40 measured by ddPCR with 3 copies of TNXA, but our PCR protocol repeatedly failed to amplify these loci, leaving the mechanism unknown. · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Three subjects with excessive ddPCR TNXB exon 40 copy number did not have a detectable TNXB-like TNXA allele, as shown in Table 1.”
§ Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X > 3. Results Amongst the 278 subjects who underwent CAH-X screening, 45 of them from 37 unrelated families (31 with 21-OHD and 6 others) had an excessive copy number of TNXB exon 40 (2.50–5.47, with 2.50 as the cutoff value) as measured by the digital droplet PCR assay. These 45 subjects were all confirmed as true CAH-X negative with a Sanger-based methodology conducted by a CLIA-accredited laboratory (PreventionGenetics, LLC, Marshfield, WI, USA). Their disease conditions included 18 patients with 21-OHD CAH (9 salt-wasting, 8 simple virilizing and 1 nonclassic), 18 carriers of 21-OHD CAH, 3 unaffected relatives of 21-OH CAH and 6 relatives of subjects with other endocrine conditions (Table 1). Forty-two subjects (93.3%, 42/45) had at least one allele of a TNXA variant homologous to the TNXB exon 40 by carrying SNPs rs4959086(C>G) and rs77471377(C>G), forty-one of them with both SNPs in tandem and one subject with rs77471377(C>G) alone. A total of 48 TNXB-exon 40-like TNXA variant alleles were detected in these 42 subjects. All 278 subjects of the cohort had previously measured C4A and C4B copy numbers by which their respective RCCX module unit numbers were determined [33]; accordingly, their respective TNXA copy numbers were also determined. There were a total of 467 TNXA alleles in the entire cohort; therefore, the allele frequency of the TNXA variant allele responsible for the excessive ddPCR TNXB exon 40 copy number was 10.3% (48/467). Amongst the 11 subjects carrying one copy of TNXA, 10 had the TNXB-like variant as their lone TNXA allele. Amongst the 27 subjects carrying two copies of TNXA, 3 had both copies and 23 had one copy as the TNXB-like variant. Amongst the seven subjects carrying three copies of TNXA, one had all three copies, one had two copies and four had one copy as the TNXB-like TNXA variant. The two SNPs were determined as in cis in all heterozygous cases by either family genotyping or TA clone sequencing, reflecting the ddPCR methodology which detects SNPs in tandem. As a control group, twenty-nine subjects confirmed negative for CAH-X and a normal range TNXB exon 40 copy number (1.7–2.4) were tested on the TNXA locus of interest. No SNP rs77471377(C>G) was detected in this group, whereas four carried a heterozygous rs4959086(C>G). Hence, this TNXB-like TNXA variant allele was indeed the predominant cause of the excessive TNXB exon 40 copy number measured by ddPCR. It was found most frequently in cis with a normal CYP21A2 allele, with 22 out of 48 alleles, or 45.8% in cis with 21 (or 20) normal CYP21A2 alleles in 19 subjects from 17 families. The second most frequent in cis CYP21A2 genotype was In2G; 12 (25.0%, 12/48) of the TNXA variant alleles shared a chromosome with 11 CYP21A2 In2G alleles in 10 subjects from six families. Other findings included: two families had a TNXA variant allele in cis with a CYP21A2 Q318X allele; one family each had a TNXA variant in cis with a CYP21A2 I172N, del-I172N and IV8 + 1G>A allele, respectively. We failed to determine the in cis CYP21A2 association of seven TNXA variant alleles due to absence of family genotype information. Thus, based on the 150 chromosomes with known normal CYP21A2 and the 93 chromosomes of In2G CYP21A2 (55 patients with 21-OHD CAH and 24 carriers) in our cohort, we found that at least 13.3% (20/150) and 11.8% (11/93) of unaffected and In2G CYP21A2 alleles shared a chromosome with one or more copies of this TNXA variant allele, respectively. Three subjects with excessive ddPCR TNXB exon 40 copy number did not have a detectable TNXB-like TNXA allele, as shown in Table 1. Subject 25A had her TNXB exon 40 copy number measured as 2.62; she had one copy of TNXA determined as wild-type which matched the reference genome in this study, thus the mechanism underlying the excessive 0.62 copy of TNXB exon 40 remains unclear. Subject 33 had the TNXB exon 40 copy number measured as 2.87; two wild-type copies of TNXA were present. This was the lone case of TNXB exon 35 being measured as 2.83 (Figure 2) without further evidence of structural variation in the loci; thus, the excessive copy numbers were likely due to some variants in the HBB gene whose copy number was used to normalize the TNXB exons in the ddPCR assays. Subject 27B had 2.92 copies of TNXB exon 40 measured by ddPCR with 3 copies of TNXA, but our PCR protocol repeatedly failed to amplify these loci, leaving the mechanism unknown.
plainn = 3- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
12 more claims
Create a free account to see all 25 claims and every source verdict.
- Probably not a substantial claim. 3
- It may state two separate claims as one. 6
Citations
Cites
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationSpeiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234 · cited 1×
“In the genetics of 21-OHD CAH, a minor conversion is defined as a small portion of the pseudogene CYP21A1P being converted to CYP21A2 to cause pathogenic defects, which include the 10 most common variants [3,14].”
BackgroundSelf-citationHigh frequency of nonclassical steroid 21-hydroxylase deficiency
SPEISER, P. W., DUPONT, B. O., RUBINSTEIN, P., PIAZZA, A., KASTELAN, A., & NEW, M. I. (1986) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-198604000-00017 · Cited by 523
A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency
Schalkwijk, J., Zweers, M. C., Steijlen, P. M., Dean, W. B., Taylor, G., van Vlijmen, I. M., van Haren, B., Miller, W. L., & Bristow, J. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa002939 · Cited by 391 · cited 2×
“Concomitant hEDS in CAH has been associated with TNXB, which encodes tenascin-X, a glycoprotein crucial in ECM composition [5,6,26].”
BackgroundHigh frequency of nonclassical steroid 21-hydroxylase deficiency.
Speiser, P., Dupont, B., Rubinstein, P., Piazza, A., Kaštelan, A., & New, M. I. (1985) · PubMed · Cited by 374
Tenascin-X deficiency is associated with Ehlers-Danlos syndrome
Burch, G. H., Gong, Y., Liu, W., Dettman, R. W., Curry, C. J., Smith, L., Miller, W. L., & Bristow, J. (1997) · Nature Genetics · doi:10.1038/ng0997-104 · Cited by 366 · cited 1×
“CYP21A1P-TNXA/TNXB chimeras are responsible for the majority of known hEDS cases amongst the CAH population, known as “CAH-X”, named for CAH with tenascin-X defects [4,5,9].”
BackgroundNew, M. I., Abraham, M., Gonzalez, B., Dumic, M., Razzaghy-Azar, M., Chitayat, D., Sun, L., Zaidi, M., Wilson, R. C., & Yuen, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300057110 · Cited by 365
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
Merke, D. P., & Auchus, R. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1909786 · Cited by 341
Self-citationTenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B
Bristow, J., Tee, M., Gitelman, S., Mellon, S., & Miller, W. (1993) · The Journal of cell biology · doi:10.1083/jcb.122.1.265 · Cited by 302 · cited 1×
“Concomitant hEDS in CAH has been associated with TNXB, which encodes tenascin-X, a glycoprotein crucial in ECM composition [5,6,26].”
Background
Cited by
Zhao, Z., Zhao, G., Li, S., Yuan, C., Feng, J. T., Tang, W., Fu, X., Li, H., Zhu, J., Zhao, X., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07735-9 · Cited by 2
“…challenges include pseudogene interference (e.g., distinguishing CYP21A2 from its pseudogene CYP21A1P [10], inadequate detection of large structural variants such as F8 intron 22 inversions (INV22) [11], and incomplete capture of sin-gle-exon copy number variations (CNVs) in genes like DMD [12–16].”
Metadata
- Authors
- Lao, Q., Zhou, K., Parker, M., Faucz, F. R., & Merke, D. P.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Lao, Qizong
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2023-01-19
- Volume
- 14
- Issue
- 2
- Pages
- 265
- ISSN
- 2073-4425 (ISSN-L)
- PMC
- PMC9956258
- OpenAlex
- W4317434809
- Cited by
- 1
- References
- 47
- Citations by year
- 2026: 1
- FWCI
- 0.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Genes (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Intramural Research Program at the National Institutes of Health (NIH)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- congenital adrenal hyperplasia, 21-hydroxylase deficiency, CYP21A2, copy number loss, digital PCR, multiplex ligation-dependent probe amplification, connective tissue dysplasia, allele frequency
- MeSH terms
- Adrenal Hyperplasia, Congenital, Genetic Testing, Humans, Pseudogenes, Steroid 21-Hydroxylase, Tenascin, Multiplex Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X. https://app.cochat.ai/papers/10.3390/genes14020265
- The paper
- Lao, Q., Zhou, K., Parker, M., Faucz, F. R., & Merke, D. P. (2023). Pseudogene TNXA Variants May Interfere with the Genetic Testing of CAH-X. Genes. https://doi.org/10.3390/genes14020265
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.